Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb study of ALX-0061 monotherapy in rheumatoid arthritis patients intolerant to methotrexate
2014-003012-36Phase 2Completed
- Sponsor
- Ablynx
- Start
- Dec 2014
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vobarilizumab in rheumatoid arthritis (RA) (2 arms), sponsored by Ablynx. Primary endpoint: ACR20 response at Week 12. Started Dec 2014; status: completed.
02
Drugs
vobarilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2014-003012-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003012-36.